R&D News | pharmaphorum

News

Novartis/Amgen migraine jab works in tough-to-treat patients

Novartis continues to build the case for its Aimovig migraine injection,with data showing it works in a tough-to-treat patient group.

News

Novartis invests $100m in new malaria drugs

Concerns are mounting over resistance to artemisinin

News

Roche haemophilia drug gets fast FDA review in expanded use

The FDA has granted ‘Breakthrough Therapy’ status for Roche’s Hemlibra (emicizumab) for people with haemophilia A without factor VIII inhibitors, as the Swiss firm aims to take market share

News

BMS begins Harvard fibrosis stem cell research collaboration

R&D link-up with Harvard Fibrosis Network

News

AZ grabs licence as Ionis NASH drug heads to the clinic

Could antisense drug be a fatty liver disease blockbuster?

News

GW Pharma and Orchard biggest UK biotech fundraisers in Q1

The UK biotech sector has enjoyed a 'solid start' in early 2018, with GW Pharma and Orchard Therapeutics dominating the funding raised.

Novartis/Amgen migraine jab works in tough-to-treat patients

Novartis invests $100m in new malaria drugs

Roche haemophilia drug gets fast FDA review in expanded use

BMS begins Harvard fibrosis stem cell research collaboration

AZ grabs licence as Ionis NASH drug heads to the clinic

GW Pharma and Orchard biggest UK biotech fundraisers in Q1

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks